KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vir Biotechnology (VIR) Net Margin (2018 - 2025)

Vir Biotechnology's Net Margin history spans 8 years, with the latest figure at 66.99% for Q4 2025.

  • On a quarterly basis, Net Margin rose 77824.0% to 66.99% in Q4 2025 year-over-year; TTM through Dec 2025 was 638.87%, a 11183.0% increase, with the full-year FY2025 number at 638.87%, up 6453.0% from a year prior.
  • Net Margin hit 66.99% in Q4 2025 for Vir Biotechnology, up from 67975.42% in the prior quarter.
  • Over the last five years, Net Margin for VIR hit a ceiling of 106.57% in Q3 2021 and a floor of 67975.42% in Q3 2025.
  • Historically, Net Margin has averaged 5825.25% across 5 years, with a median of 457.33% in 2023.
  • Biggest five-year swings in Net Margin: soared 859021bps in 2022 and later tumbled -5899571bps in 2025.
  • Tracing VIR's Net Margin over 5 years: stood at 64.63% in 2021, then crashed by -418bps to 205.63% in 2022, then tumbled by -236bps to 690.85% in 2023, then fell by -22bps to 845.23% in 2024, then surged by 92bps to 66.99% in 2025.
  • Business Quant data shows Net Margin for VIR at 66.99% in Q4 2025, 67975.42% in Q3 2025, and 9139.87% in Q2 2025.